Stuart L. Goldstein, MD, FAAP, FNKF

Director, Center for Acute Care Nephrology

Medical Director, Pheresis Service

Co-Medical Director, Heart Institute Research Core

Professor, UC Department of Pediatrics

Phone 513-803-3295

Fax 513-636-6407

Email stuart.goldstein@cchmc.org

Clinical Interests

Acute kidney injury; continuous renal replacement therapy; cardio-renal syndrome; nephrotoxic medication associated morbidity

Research Interests

Acute kidney injury epidemiology and biomarkers; heart failure associated chronic kidney disease; nephrotoxic medication associated acute kidney injury reduction

Stuart L. Goldstein, MD, has been an active investigator in the field of pediatric acute kidney injury (AKI) since 2000.  Dr. Goldstein’s main research foci include: AKI epidemiology and outcomes, acute renal replacement therapy provision and investigation of novel urinary AKI biomarkers in the pediatric population. Dr. Goldstein has established a strong record of interdisciplinary and inter-institutional collaboration with cardiologists, intensivists and emergency center physicians, which is evidenced by his establishment and directing of the Prospective Pediatric Continuous Renal Replacement Therapy Registry from 2001 to 2012, and the Prospective Pediatric AKI Research Group (ppAKI-RG) in 2012. The ppAKI-RG is comprised of 39 centers from around the world with the goal of improving outcomes for the child with or at-risk for, AKI. 

Dr. Goldstein has led initial efforts to develop a standardized definition for pediatric AKI, assess novel AKI biomarkers in heterogeneous populations, and conceiving and validating stratification tools to identify patients at risk for AKI. Building up these findings, Dr. Goldstein embarked on establishing the ppAKI-RG consortium to focus on multi-centered research studies that are dedicated to understanding and treating AKI in pediatric patients.  Currently, the ppAKI-RG has initiated three major, and unprecedented, national and international studies (AWARE, NINJA and DIRECT) to reduce AKI and improve patient outcomes. Dr. Goldstein is also a recognized educator; he has developed the only pediatric specific acute care nephrology sub-specialty fellowship with graduates who are now leaders in the field of pediatric AKI.

MD: Columbia College of Physicians and Surgeons, New York, NY, 1990.

Residency: Baylor College of Medicine, Houston, TX.

Fellowship: Pediatric Nephrology, Children's Hospital, Boston, MA.

Inflammation, malnutrition and cardiac calcification in pediatric ESRD patients receiving dialysis. Principal Investigator. Casey Lee Ball Foundation. Jan 2010 - Dec 2020.

Use of NGAL to Optimize Fluid Dosing, CRRT Initiation and Discontinuation in Critically Ill Children with Acute Kidney Injury. Principal Investigator. Gambro Renal Products. Nov 2011-Jan 2017.

Clinical Evaluation of the Prismaflex™ HF20 Set and Prismaflex™Control Unit Version 5.10 Software for Acute Continuous Renal Replacement Therapy (CRRT) in Children. Principal Investigator. Gambro Renal Products, Inc. Mar 2014–Mar 2016.

Reduction of Nephrotoxic Medication Associated Acute Kidney Injury in Children: Dissemination of a Successful Quality Improvement Project. Principal Investigator. Casey Lee Ball Foundation. Feb 2013–Jun 2015.

An Observational, Genomic Study of Patients with Drug Induced Kidney Injury. Principal Investigator. International SAE Consortium, LTD. May 2013-Dec 2015.

Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care. Principal Investigator. NICHD Pediatric Trials Network-POPS. Feb 2013–Feb 2017.

Antibiotic Safety in Infants with Complicated Intra-Abdominal Infections (SCAMP Trial). Principal Investigator. NICHD-2013-ABS01 Pediatric Trials Network. May 2014–Sep 2017.

Recombinant Erythropoietin Protects Against Kidney Disease. Principal Investigator. National Institutes of Health. Sep 2014–Aug 2019.

Reduction of Nephrotoxic Medication Associated Acute Kidney Injury in Children: Dissemination of a Successful Quality Improvement Project. Principal Investigator. Agency for Healthcare Research and Quality. Apr 2015–Mar 2018.